Ad
CERC - Cerecor Stock Trading
About | Cerecor Inc. (NASDAQ:CERC)
Not available
Quote | Cerecor Inc. (NASDAQ:CERC)
| Last: | $2.93 |
|---|---|
| Change Percent: | -1.68% |
| Open: | $2.98 |
| Close: | $2.93 |
| High: | $2.98 |
| Low: | $2.9 |
| Volume: | 266,862 |
| Last Trade Date Time: | 08/25/2021 04:41:35 am |
News | Cerecor Inc. (NASDAQ:CERC)
-
Successfully eliminated $35 million debt paving the way for future growth and innovation Divested AVTX-800 series for potential milestone payments of $45 million, fully focusing the pipeline on Avalo’s promising immunology assets Disclosed improved cash of approximately $10.2 mil...
-
WAYNE, Pa. and ROCKVILLE, Md., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced it has completed the divestiture of its rights, title and interest in, assets relating to AVTX-801 (D-galactose), AVTX-802 (D-mannose) and AVTX-803 (L-fucose) (collective...
Message Board Posts | Cerecor Inc. (NASDAQ:CERC)
| Subject | By | Source | When |
|---|---|---|---|
| New board is: https://investorshub.advfn.com/Avalo-Therapeutics-AVTX-40053/ | AliasUser1 | investorshub | 09/14/2021 10:00:46 PM |
| $cerc Cerecor wins Fast Track Designation https://www.biospace.com/article/2021- | frankkruemmel | investorshub | 05/11/2021 4:41:12 PM |
| And up 25% this morning | JohnLocke101 | investorshub | 05/11/2021 1:43:22 PM |
| Biggest negative operating margin ever seen -706.02%, book | make it happen | investorshub | 05/11/2021 1:28:10 PM |
| https://www.marketwatch.com/story/cerecors-investigational-covid-19-therapy-gets | frankkruemmel | investorshub | 05/11/2021 1:13:09 PM |
News, Short Squeeze, Breakout and More Instantly...
Ad
-
Successfully eliminated $35 million debt paving the way for future growth and innovation Divested AVTX-800 series for potential milestone payments of $45 million, fully focusing the pipeline on Avalo’s promising immunology assets Disclosed improved cash of approximately $10.2 mil...
-
WAYNE, Pa. and ROCKVILLE, Md., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced it has completed the divestiture of its rights, title and interest in, assets relating to AVTX-801 (D-galactose), AVTX-802 (D-mannose) and AVTX-803 (L-fucose) (collective...
-
WAYNE, Pa. and ROCKVILLE, Md., Sept. 26, 2023 (GLOBE NEWSWIRE) -- In a major achievement, Avalo Therapeutics (Nasdaq: AVTX) proudly announces the payoff of the remainder of its $35 million debt owed to Horizon Technology Finance Corporation (Nasdaq: HRZN). This significant milestone not only sign...